Warning: mysqli_query(): (HY000/1): Can't create/write to file '/tmp/#sql_4f7_1.MYI' (Errcode: 28 - No space left on device) in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
EPS for Agenus Inc. (AGEN) Expected At $-0.25 - Money Making Articles Hot Stuff

EPS for Agenus Inc. (AGEN) Expected At $-0.25

October 13, 2018 - By Vivian Park

Agenus Inc. (NASDAQ:AGEN) LogoInvestors sentiment decreased to 1.02 in Q2 2018. Its down 0.44, from 1.46 in 2018Q1. It fall, as 22 investors sold Agenus Inc. shares while 21 reduced holdings. 17 funds opened positions while 27 raised stakes. 40.51 million shares or 12.82% less from 46.47 million shares in 2018Q1 were reported.
Blackrock invested 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Ubs Asset Mgmt Americas Incorporated, Illinois-based fund reported 132,999 shares. 600 are owned by Pnc Financial Gp. Financial Bank Of Montreal Can reported 0% stake. Illinois-based Northern Tru has invested 0% in Agenus Inc. (NASDAQ:AGEN). California Public Employees Retirement Sys reported 142,317 shares. Tiaa Cref Inv Mgmt Ltd Liability Co stated it has 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Amer Grp Incorporated holds 52,085 shares. Stifel Fincl accumulated 0% or 10,066 shares. Moreover, Fmr Ltd Co has 0% invested in Agenus Inc. (NASDAQ:AGEN). Qvt Fincl Limited Partnership holds 0.93% or 1.47M shares in its portfolio. Moreover, Proshare Advisors Limited Liability Corporation has 0% invested in Agenus Inc. (NASDAQ:AGEN) for 10,531 shares. Moreover, Barclays Public Ltd Limited Liability Company has 0% invested in Agenus Inc. (NASDAQ:AGEN) for 73,320 shares. Artal Gp holds 0.13% or 2.75M shares. Victory Capital Mgmt stated it has 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN).

Analysts expect Agenus Inc. (NASDAQ:AGEN) to report $-0.25 EPS on November, 6.They anticipate $0.12 EPS change or 32.43 % from last quarter’s $-0.37 EPS. After having $-0.24 EPS previously, Agenus Inc.’s analysts see 4.17 % EPS growth. The stock decreased 2.50% or $0.05 during the last trading session, reaching $1.95. About 704,625 shares traded. Agenus Inc. (NASDAQ:AGEN) has declined 53.28% since October 13, 2017 and is downtrending. It has underperformed by 68.90% the S&P500.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The company has market cap of $220.90 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

More important recent Agenus Inc. (NASDAQ:AGEN) news were published by: Nasdaq.com which released: “Recent Analysis Shows Ryman Hospitality Properties, PennantPark Investment, PS Business Parks, Agenus, Belden …” on October 08, 2018, also Prnewswire.com published article titled: “Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018”, Seekingalpha.com published: “Agenus secures $40M capital raise” on October 11, 2018. More interesting news about Agenus Inc. (NASDAQ:AGEN) was released by: Benzinga.com and their article: “26 Stocks Moving In Thursday’s Pre-Market Session” with publication date: October 11, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:



Warning: mysqli_query(): (HY000/1): Can't create/write to file '/tmp/#sql_4f7_1.MYI' (Errcode: 28 - No space left on device) in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
>